Association between factor V Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations and events of the arterial circulatory system: A meta-analysis of published studies

American Heart Journal

Volumn 146, Issue 6, 2003, Pages 948-957

  Kim, Robert J ^a   Becker, Richard C ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; PROTHROMBIN;

ADULT; ARTERIAL CIRCULATION; ARTERY THROMBOSIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0344196959     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00519-2     Document Type: Article

References (97)

1. Bertina RM, Koeleman BPC, Koster T. Mutations in blood coagulation Factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
2. Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
3. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330:517-22.
4. Poort SR, Rosendaal FR, Reitsma PH. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
5. Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor For venous thromboembolic disease. Arch Intern Med 1998;158: 2101-6.
6. Bogardus ST, Concado J, Feinstein AR. Clinical epidemiological quality in molecular genetic research: the need For methodological standards. JAMA 1999;281:1919-26.
7. Little J, Bradley L, Bray MS. Reporting appraising and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002;156:300-10.
8. Egger M, Sterne JAC, Smith GD. Meta-analysis software. Brit Med J 1998;316:7126.
9. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
10. Morita H, Kurihara H, Sugiyama T. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol 1999;19:298-302.
11. Rassoul F, Richter V, Janke C. Plasma homocysteine and lipoprotein profile in patients with peripheral arterial occlusive disease. Angiology2000;51:189-96.
12. Iniesta J, Corral J, Fernandez-Pardo J. Factor-V (Arg506→Gln) mutation in ischemic cerebrovascular disease. Haemostasis 1997; 27:105-11.
13. Catto A, Carter A, Ireland H. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb Vasc Biol 1995;15:783-5.
14. Araujo F, Santos A, Araujo V. Genetic risk factors in acute coronary disease. Haemostasis 1999;29:212-8.
15. Arruda V, Annichino-Bizzacchi JM, Gonçalves MS. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430-3.
16. Arruda VR, Siquiera LH, Chiaparini LC. Prevalence of the prothrombin gene variant 20210G→A among patients with myocardial infarction. Cardiovasc Res 1998;37:42-5,
17. Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. Kobe J Med Sci 2001;47:255-62.
18. Virgos C, Joven J, Simo JM. Homocysteine and the C677T mutation of methylenetetrahydrofolate reductase in survivors of premature myocardial infarction. Clin Biochem 2000;33:509-12.
19. D'Angelo A, Coppola A, Madonna P. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. Thromb Haemost 2000;83:563-70.
20. Dilley A, Hooper WC, El-Jamil M. Mutations in the genes regulating methylenetetrahydrofolate reductase (MTHFR C→T677) and cystathione β-synthase (CBS G→A919, CBS T→c833) are not associated with myocardial infarction in African Americans. Thromb Res 2001;103:109-15.
21. Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. Thromb Res 2001;104:187-95.
22. Press RD, Liu XY, Beamer N. Ischemic stroke in the elderly: role of the common factor V Leiden mutation causing resistance to activated protein C. Stroke 1996;27:44-8.
23. Wang XL, Wang J, McCredie RM. Polymorphisms of factor V, factor VII, and fibrinogen genes: relevance to severity of coronary artery disease. Arterioscler Thromb Vasc Biol 1997;17:246-51.
24. Redondo M, Watzke HH, Stucki B. Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease. Arterioscler Thromb Vasc Biol 1999;19:1020-5.
25. Holm J, Zoller B, Berntorp E. Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239: 221-6.
26. Baranovskaya S, Kudinov S, Fomicheva E. Age as a risk factor for myocardial infarction in Leiden mutation carriers. Mol Genet Metab 1998;63:155-7.
27. Corral J, Gonzalez-Conejero R, Lozano ML. The venous thrombosis risk factor 20210A allele of prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol 1997;99: 304-7.
28. Dilley A, Harland A, Hooper WC. Prevalence of the prothrombin 20210 G-to-A variant in blacks: infants, patients with venous thrombosis, patients with myocardial infarction, and control subjects. J Lab Clin Med 1998;132:452-5.
29. Prohaska W, Mannebach H, Schimidt M. Evidence against heterozygous coagulation factor V 1691 G→A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med 1995;73:521-4.
30. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99:999-1004.
31. Croft SA, Daly ME, Steeds RP. The prothrombin 20210A allele and its association with myocardial infarction. Thromb Haemost 1999;81:861-4.
32. Doggen CJM, Cats VM, Bertina RM. Interaction of coagulation defects and cardiovascular risk factors. Circulation 1998;97: 1037-41.
33. Rosendaal FR, Siscovick DS, Schwartz SM. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-21.
34. Ridker PM, Hennekens CH, Lindpainter K. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
35. Eikelboom JW, Baker RI, Parsons R. No association between the 20210G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost 1998;80:878-80.
36. Rosendaal FR, Siscovick DS, Schwartz SM. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-50.
37. Ardissino D, Peyvandi F, Merlini PA. Factor V (Arg506→Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996;75:701-2.
38. Inbal A, Freimark D, Modan B. Synergistic effects of prothrombotic polymorphisms and atherogenic factors on the risk of myocardial infarction in young males. Blood 1999;93:2186-90.
39. Cushman M, Rosendaal FR, Psaty BM. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998;79:912-5.
40. Gardemann A, Arsic T, Katz N. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. Thromb Haemost 1999;81:208-13.
41. Anderson J, King GJ, Thomson MJ. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol 1997;30:1206-11.
42. Makris TK, Krespi PG, Hatzizacharias AN. Resistance to activated protein C and FV Leiden mutations in patients with a history of acute myocardial infarction or primary hypertension. Am J Hypertens 2000;13:61-5.
43. Ardissino D, Mannucci PM, Merlini PA. Prothrombotic genetic risk factors in young survivors of myocardial infarction. Blood 1999; 94:46-51.
44. Gowda MS, Zucker ML, Vacek JL. Incidence of factor V Leiden in patients with acute myocardial infarction. J Thromb Thrombolysis 2000;9:43-5.
45. Russo C, Girelli D, Olivieri O. G20210A prothrombin gene polymorphism and prothrombin activity in subjects with or without angiographically documented coronary artery disease. Circulation 2001;103:2436-40.
46. Feng YJ, Draghi A, Linfert DR. Polymorphism in the genes for coagulation factors II, V, and VII in patients with ischemic heart disease. Arch Pathol Lab Med 1999;123:1230-5.
47. Kontula K, Ylikorkala A, Miettinen H. Arg506Gln factor V mutation (factor V Leiden) in patients with ischemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 1995;73:558-60.
48. Franco RF, Trip MD, ten Cate H. The 20210G to A mutation in the 3′-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. Br J Haemotol 1999;104:50-4.
49. Mansourati J, Da Costa A, Munier S. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. Thromb Haemost 2000;83:822-5.
50. Burzotta F, Paciaroni K, de Stefano V. Increased prevalence of the G20210A prothrombin gene variant in acute coronary syndromes without metabolic or acquired risk factors or with limited extent of disease. Eur Heart J 2002;23:26-30.
51. Junker R, Heinrich J, Schulte H. Plasminogen activator inhibitor-1 4G/5G-polymorphism and factor V Q506 mutation are not associated with myocardial infarction in young men. Blood Coagul Fibrinolysis 1998;9:597-602.
52. Smiles AM, Jenny NS, Tang Z. No association of plasma prothrombin concentration or the G20210A mutation with incident cardiovascular disease. Thromb Haemost 2002;87:614-21.
53. Gardemann A, Weidemann H, Philipp M. The TT genotype of the methylenetetrahydrofolate reductase C677T gene polymorphism is associated with the extent of coronary atherosclerosis in patients at high risk for coronary artery disease. Eur Heart J 1999;20:584-92.
54. Lopaciuk S, Bykowska K, Kwiecinski H. Factor V Leiden, prothrombin G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. Clin Appl Thromb Haemost 2001;7:346-50.
55. Longstreth WT, Rosendaal FR, Siscovick DS. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A), Stroke 1998;29:577-80.
56. de Stefano V, Chiusolo P, Paciaroni K. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. Blood 1998;91:3562-5.
57. Markus HS, Zhang Y, Jeffery S. Screening for the factor-V Arg 506Gln mutation in patients with TIA and stroke. Cerebrovasc Dis 1996;6:360-2.
58. Fisher M, Fernandez J, Ameriso SF. Activated protein C resistance in ischemic stroke not due to factor V Arg506→Glutamine mutation. Stroke 1996;27:1163-6.
59. Nabavi DG, Junker R, Wolff E. Prevalence of factor V Leiden mutation in young adults with cerebral ischemia: a case-control study on 225 patients. J Neurol 1998;245:653-8.
60. Margaglione M, D'Andrea G, Giuliani N, Inherited prathrombotic conditions and premature ischemic stroke. Arterioscler Thramb Vasc Biol 1999;19:1751-6.
61. Lalouschek W, Aull S, Serles W. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. Thromb Res 1999;93:61-9.
62. Ferrerasi P, Marchetti G, Legnani E. The heterozygous 20210G/A prathrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increase in frequency in artery disease. Arterioscler Thromb Vasc Biol 1997;17:2418-22.
63. Hankey GJ, Eikelboom JW, van Bockxmeer FM. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001;321:1793-9.
64. Madanna P, de Stefano V, Coppola A. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002;33:51-6.
65. Pezzini A, Del Zotto E, Archetti S. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherathrombotic stroke. Stroke 2002;33:664-9.
66. Morita H, Kurihara H, Tsubaki S. Methylenetetrahydrofalate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 1998;18:1465-9.
67. Markus HS, Ali N, Swaminathan R. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 1997;28:1739-43.
68. Harmon D, Doyle RM, Meleady R. Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrafolate reductose as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 1999;99:208-11.
69. Vaetsch B, Damasceno BP, Camargo ESC. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost 2000;83:229-33.
70. Girelli D, Friso S, Trabetti E. Methylenetetrahydrofolate reductase C677T mutation, plasma homocysteine, and folate in subjects from northern Italy with or without angiographically documented severe coronary atherosclerotic disease: evidence for an important genetic-environmental interaction. Blood 1998;91:4158-63.
71. Ma J, Stampfer MJ, Hennekens CH. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physician. Circulation 1996;94:2410-6.
72. Adams M, Smith PD, Martin D. Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. QJM 1996;89:437-44.
73. Schwartz SM, Siscovick DS, Malinow R. Myocardial infarction in young women in relation to plasma total homocysteine, folate and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-7.
74. van Bockxmeer FM, Mamotte CDS, Vasikaran SD. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997;95:21-3.
75. Schmitz C, Lindpainter K, Verhoef P. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. Circulation 1996;94:1812-4.
76. Brugada R, Marian AJ. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis 1997;128:107-12.
77. Juul K, Tybjarg-Hansen A, Steffensen R. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 2002; 100:3-10.
78. Renner W, Kappen H, Brodmann M. Factor II G20210A and factor V G1691A gene mutations and peripheral arterial occlusive disease. Thromb Haemost 2000;83:20-2.
79. Krinstensen B, Malm J, Nilsson TK. Hyperhomocysteinemia and hypafibrinolysis in young adults with ischemic stroke. Stroke 1999; 30:974-80.
80. Szalnoki Z, Somogyvari F, Kondacs A. Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischemic stroke. J Neural 2001;248:756-61.
81. Celik S, Ovali E, Baykan M. Factor V Leiden and its relation ta left ventricular thrombus in acute myocardial infarction. Acta Cardiol 2001;56:1-6.
82. Psaty BM, Smith NL, Lemaitre RN. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001;285:906-13.
83. Fernandez-Arcas N, Dieguez-Lucena JL, Munoz-Moran E. The genotype interactions of methylenetetrahydrofolate reductase and renin-angiotensin system genes are associated with myocardial infarction. Atherosclerosis 1999;145:293-300.
84. Thogersen AM, Nilsson TK, Dahlen G. Hamozygosity for the C677→T mutation of 5, 10-methylenetetrahydrofalate reductase and total plasma homocyst(e)ine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. Coron Artery Dis 2001;12:85-90.
85. Gule 86 S, Aras O, Akar E. Methylenetetrahydrofolate reductase gene polymorphism and risk of premature myacardial infarction. Clin Cardiol 2001;24:281-4.
86. Thomas DP. Overview of venous thrombogenesis. Semin Thromb Haemost 1988;68:329-37.
87. Mustard JF, Packham MA, Kinlough-Rathbone RI. Platelets, blood flow, and the vessel wall. Circulation 1990;81(1 Suppl):124-7.
88. Burke AP, Farb A, Pestaner J. Traditional risk factors and the incidence of sudden coronary death with and without coronary thrombosis in blacks. Circulation 2002;105:419-24.
89. Dahlbock B. Resistance to activated protein C as a risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 1997;34:217-34.
90. Nowak-Gottl U, Strater R, Heinecke A. Lipoprotein(a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischaemic stroke in childhood. Blood 1999;94:3678-82.
91. Vondenbroucke JP, Koster T, Briet E. Increased risk of venous thrombosis in orol contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453.
92. Rosendoal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002;22: 201-10.
93. Tremoli E, Camera M, Toschi V. Tissue factor in atherosclerosis. Atherosclerosis 1999;144:273-83.
94. Cella G, Burlina A, Sborai A. Tissue factor pathway inhibitor levels in patients with homocysteinuria. Thromb Res 2000;98:375-81.
95. 506→Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting. Thromb Haemost 1998;80: 220-4.
96. French JK, Van de Woter NS, Sutton TM. Potential thrombophilic mutations/polymorphism in patients with no flow-limiting stenosis after myocardial infarction. Am Heart J 2003;145:118-24.
97. Klerk M, Verhoef P, Clarke R. MTHFR 677C→T polymorphism ond risk of coronary heart disease. JAMA 2002;288:2023-31.